The Heidelberg Engineering BI US Evaluation Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10036
- State University of New York College of Optometry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Subjects with:
- Eyes with Normal Anterior Segment or
- Eyes with Abnormal Anterior Segment, including Eyes with Cataract Eyes without a Crystalline Lens Eyes with Corneal Abnormality Eyes with Anterior Segment Pathology
Description
Inclusion Criteria:
- Age 18 years or older
Able and willing to undergo the test procedures, sign informed consent, and follow instructions
At least one of the following:
- Eyes with Normal Anterior Segment
- Eyes with Cataract
- Eyes without a Crystalline Lens
- Eyes with Corneal Abnormality
- Eyes with Anterior Segment Pathology
Exclusion Criteria:
- Subjects unable to read or write
- Active infection or inflammation in one or both eyes
- Insufficient tear film or corneal reflex
- Physical inability to be properly positioned at the study devices or eye exam equipment
- Inability to fixate
- Rigid contact lens wear during past 2 weeks
- Soft lenses, in the study eye, if worn, should be removed at least one hour prior to the measurements *Note: Eyes with risk for acute angle closure glaucoma are excluded from the dilated portion of the study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Anterior Segment Pathology
single measurement Anterior Segment Pathology
|
Single eye measurement in Anterior Segment Mode
|
|
All except Anterior Segment Pathology
3 repeat measurements with and without dilation for all eyes except Anterior Segment Pathology
|
Eye measurement 3 times with and without dilation in IOL biometry and Anterior Segment mode
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of successfully scanned biometry images of the eye
Time Frame: 1 day
|
Percentage of successfully scanned biometry images of the eyes per scan mode.
Success is defined as agreement of the subjective assessment of the operator and the auto assessment of the device.
|
1 day
|
|
Repeatabiltiy of specific parameters of the biometry images of the eye
Time Frame: 1 day
|
Repeatability of specific parameters stratified by different eye pathologies
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mitchell Dul, OD, State University of New York College of Optometry
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B-2018-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.